{"title":"Expression of aquaporin 1, 3 and 5 in colorectal carcinoma: correlation with clinicopathological characteristics and prognosis.","authors":"Guangwen Zhang, Yongfei Hao, Ling Chen, Zengshan Li, Langlang Gao, Jian Tian, Qing Qiao, Jinsong Zhang","doi":"10.3389/pore.2023.1611179","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Prognostic biomarkers in colorectal carcinoma (CRC) have an important role in therapeutic strategy. Studies have shown that high expression of Aquaporin (AQP) is associated with poor prognosis in a variety of human tumors. AQP is involved in the initiation and development of CRC. The present study aimed to investigate the correlation between the expression of AQP1, 3 and 5 and clinicopathological features or prognosis in CRC. <b>Methods:</b> The AQP1, 3 and 5 expressions were analyzed based on the immunohistochemical staining of tissue microarray specimens including 112 patients with CRC between June 2006 and November 2008. The expression score of AQP (Allred_score and H_score) was digitally obtained with Qupath software. Patients were divided into high or low expression subgroups based on the optimal cut-off values. The relationship between expression of AQP and clinicopathological characteristics were evaluated using chi-square test, t-test, or one-way ANOVA, when appropriate. Survival analysis of 5-year progression free survival (PFS) and overall survival (OS) was performed with time-dependent ROC, Kaplan-Meier curves, univariate and multivariate COX analysis. <b>Results:</b> The AQP1, 3 and 5 expressions were associated with regional lymph node metastasis, histological grading, and tumor location in CRC, respectively (<i>p</i> < 0.05). Kaplan-Meier curves showed that patients with high AQP1 expression had worse 5-year PFS than those with low AQP1 expression (Allred_score: 47% vs. 72%, <i>p</i> = 0.015; H_score: 52% vs. 78% <i>p</i> = 0.006), as well as 5-year OS (Allred_score: 51% vs. 75%, <i>p</i> = 0.005; H_score: 56% vs. 80%, <i>p</i> = 0.002). Multivariate Cox regression analysis indicated that AQP1 expression was an independent risk prognostic factor (<i>p</i> = 0.033, HR = 2.274, HR95% CI: 1.069-4.836). There was no significant correlation between the expression of AQP3 and 5 and the prognosis. <b>Conclusion:</b> The AQP1, 3 and 5 expressions correlate with different clinicopathological characteristics and the AQP1 expression may be a potential biomarker of prognosis in CRC.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272351/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2023.1611179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Prognostic biomarkers in colorectal carcinoma (CRC) have an important role in therapeutic strategy. Studies have shown that high expression of Aquaporin (AQP) is associated with poor prognosis in a variety of human tumors. AQP is involved in the initiation and development of CRC. The present study aimed to investigate the correlation between the expression of AQP1, 3 and 5 and clinicopathological features or prognosis in CRC. Methods: The AQP1, 3 and 5 expressions were analyzed based on the immunohistochemical staining of tissue microarray specimens including 112 patients with CRC between June 2006 and November 2008. The expression score of AQP (Allred_score and H_score) was digitally obtained with Qupath software. Patients were divided into high or low expression subgroups based on the optimal cut-off values. The relationship between expression of AQP and clinicopathological characteristics were evaluated using chi-square test, t-test, or one-way ANOVA, when appropriate. Survival analysis of 5-year progression free survival (PFS) and overall survival (OS) was performed with time-dependent ROC, Kaplan-Meier curves, univariate and multivariate COX analysis. Results: The AQP1, 3 and 5 expressions were associated with regional lymph node metastasis, histological grading, and tumor location in CRC, respectively (p < 0.05). Kaplan-Meier curves showed that patients with high AQP1 expression had worse 5-year PFS than those with low AQP1 expression (Allred_score: 47% vs. 72%, p = 0.015; H_score: 52% vs. 78% p = 0.006), as well as 5-year OS (Allred_score: 51% vs. 75%, p = 0.005; H_score: 56% vs. 80%, p = 0.002). Multivariate Cox regression analysis indicated that AQP1 expression was an independent risk prognostic factor (p = 0.033, HR = 2.274, HR95% CI: 1.069-4.836). There was no significant correlation between the expression of AQP3 and 5 and the prognosis. Conclusion: The AQP1, 3 and 5 expressions correlate with different clinicopathological characteristics and the AQP1 expression may be a potential biomarker of prognosis in CRC.
背景:结直肠癌(CRC)的预后生物标志物在治疗策略中具有重要作用。研究表明,在多种人类肿瘤中,水通道蛋白(AQP)的高表达与预后不良有关。AQP参与了CRC的发生和发展。本研究旨在探讨AQP1、3和5的表达与结直肠癌临床病理特征或预后的关系。方法:对2006年6月~ 2008年11月112例结直肠癌患者组织芯片标本进行免疫组化染色,分析AQP1、3、5的表达。采用Qupath软件数字化获取AQP表达评分(Allred_score和H_score)。根据最佳临界值将患者分为高表达亚组和低表达亚组。采用卡方检验、t检验或单因素方差分析评估AQP表达与临床病理特征的关系。采用随时间变化的ROC、Kaplan-Meier曲线、单因素和多因素COX分析进行5年无进展生存期(PFS)和总生存期(OS)的生存分析。结果:AQP1、aq3、aq5的表达分别与结直肠癌的区域淋巴结转移、组织学分级、肿瘤位置相关(p < 0.05)。Kaplan-Meier曲线显示AQP1高表达患者的5年PFS较AQP1低表达患者差(Allred_score: 47% vs. 72%, p = 0.015;H_score: 52% vs. 78% p = 0.006),以及5年OS (Allred_score: 51% vs. 75%, p = 0.005;H_score: 56% vs. 80%, p = 0.002)。多因素Cox回归分析显示AQP1表达是独立的危险预后因素(p = 0.033, HR = 2.274, HR95% CI: 1.069 ~ 4.836)。AQP3、5的表达与预后无明显相关性。结论:AQP1、3和5的表达与不同的临床病理特征相关,AQP1的表达可能是结直肠癌预后的潜在生物标志物。
期刊介绍:
Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.